Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This research is being done to determine if early changes on a type of imaging procedure
called PET (Positron Emission Tomography) can predict which patients are most likely to
respond to the combination of trastuzumab and pertuzumab when given prior to surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Genentech, Inc. Translational Breast Cancer Research Consortium